These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 3421908

  • 21. The alternative pathway of complement.
    Pangburn MK, Müller-Eberhard HJ.
    Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
    [No Abstract] [Full Text] [Related]

  • 22. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A, Isaacs SN, Soulika AM, Lambris JD.
    J Immunol; 1998 Jun 01; 160(11):5596-604. PubMed ID: 9605165
    [Abstract] [Full Text] [Related]

  • 23. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
    Fishelson Z, Müller-Eberhard HJ.
    Mol Immunol; 1983 Mar 01; 20(3):309-15. PubMed ID: 6553181
    [Abstract] [Full Text] [Related]

  • 24. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT, Austen KF.
    J Exp Med; 1977 Jul 01; 146(1):22-33. PubMed ID: 559720
    [Abstract] [Full Text] [Related]

  • 25. Activation of the alternative complement pathway.
    Fearon DT.
    CRC Crit Rev Immunol; 1979 Nov 01; 1(1):1-32. PubMed ID: 162484
    [No Abstract] [Full Text] [Related]

  • 26. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB, Thiel S, Teisner B, Holmskov U, Wang Y, Sim RB, Jensenius JC.
    Immunology; 1994 Apr 01; 81(4):648-54. PubMed ID: 7518801
    [Abstract] [Full Text] [Related]

  • 27. Complement alternative pathway activation in human nonalcoholic steatohepatitis.
    Segers FM, Verdam FJ, de Jonge C, Boonen B, Driessen A, Shiri-Sverdlov R, Bouvy ND, Greve JW, Buurman WA, Rensen SS.
    PLoS One; 2014 Apr 01; 9(10):e110053. PubMed ID: 25299043
    [Abstract] [Full Text] [Related]

  • 28. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR, Kok DJ, Van Es LA.
    Clin Exp Immunol; 1982 Oct 01; 50(1):209-14. PubMed ID: 6216999
    [Abstract] [Full Text] [Related]

  • 29. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E, Kazatchkine MD, Mecarelli-Halbwachs L.
    Eur J Immunol; 1984 Dec 01; 14(12):1111-4. PubMed ID: 6240408
    [Abstract] [Full Text] [Related]

  • 30. The mechanism of activation of the alternative pathway of complement by cell-bound C4b.
    Farries TC, Steuer KL, Atkinson JP.
    Mol Immunol; 1990 Nov 01; 27(11):1155-61. PubMed ID: 2247091
    [Abstract] [Full Text] [Related]

  • 31. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK.
    J Immunol; 1986 Mar 15; 136(6):2216-21. PubMed ID: 2419425
    [Abstract] [Full Text] [Related]

  • 32. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
    Mold C, Medof ME.
    Mol Immunol; 1985 May 15; 22(5):507-12. PubMed ID: 3848661
    [Abstract] [Full Text] [Related]

  • 33. Properdin binding to complement activating surfaces depends on initial C3b deposition.
    Harboe M, Johnson C, Nymo S, Ekholt K, Schjalm C, Lindstad JK, Pharo A, Hellerud BC, Nilsson Ekdahl K, Mollnes TE, Nilsson PH.
    Proc Natl Acad Sci U S A; 2017 Jan 24; 114(4):E534-E539. PubMed ID: 28069958
    [Abstract] [Full Text] [Related]

  • 34. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE, Balber AE.
    Exp Parasitol; 1987 Jun 24; 63(3):260-71. PubMed ID: 3556206
    [Abstract] [Full Text] [Related]

  • 35. Expression and characterisation of the thrombospondin type I repeats of human properdin.
    Perdikoulis MV, Kishore U, Reid KB.
    Biochim Biophys Acta; 2001 Aug 13; 1548(2):265-77. PubMed ID: 11513971
    [Abstract] [Full Text] [Related]

  • 36. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ, Baker PJ, Rosse WF.
    J Clin Invest; 1982 Feb 13; 69(2):337-46. PubMed ID: 6915939
    [Abstract] [Full Text] [Related]

  • 37. A molecular concept of the properdin pathway.
    Medicus RG, Schreiber RD, Götze O, Müller-Eberhard HJ.
    Proc Natl Acad Sci U S A; 1976 Feb 13; 73(2):612-6. PubMed ID: 54923
    [Abstract] [Full Text] [Related]

  • 38. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK, Schreiber RD, Müller-Eberhard HJ.
    J Exp Med; 1981 Sep 01; 154(3):856-67. PubMed ID: 6912277
    [Abstract] [Full Text] [Related]

  • 39. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL, Isenman DE.
    J Biol Chem; 1987 Feb 05; 262(4):1519-25. PubMed ID: 3643213
    [Abstract] [Full Text] [Related]

  • 40. Properdin: initiation of alternative complement pathway.
    Fearon DT, Austen KF.
    Proc Natl Acad Sci U S A; 1975 Aug 05; 72(8):3220-4. PubMed ID: 1059108
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.